Drugs · acquisition-cost intelligence
Fenofibrate
· ingredient fenofibrate· FENOFIBRATE 200 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.16790
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other fenofibrate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Fenofibrate | $0.08557 | −$0.08230 |
| fenofibrate | $0.11260 | −$0.05530 |
| Tricor | $0.11985 | −$0.04800 |
| fenofibrate | $0.12388 | −$0.04400 |
| FENOFIBRIC ACID DELAYED-RELEASE | $0.25649 | +$0.08860 |
| ANTARA | $0.66591 | +$0.49800 |
| fenofibrate | $5.82 | +$5.65 |
Medicare Part D coverage · CY2026
On 322 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 20% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.